印度取消Novartis对心脏药物Vymada的专利, 允许非专利药品降低成本。 India revoked Novartis' patent for heart drug Vymada, allowing generics to lower costs.

印度专利局以缺乏新颖性和创造性的举动为由, 撤销了诺华大学对心脏药物Vymada(Entresto)的专利权。 India's Patent Office has revoked Novartis' patent for its cardiac drug Vymada (Entresto), citing lack of novelty and inventive step. 该决定于2025年9月12日生效,为印度非专利药制造商生产成本较低的药物版本铺平了道路,有可能改善心脏病和高血压患者获得药物的机会。 The decision, effective September 12, 2025, clears the way for Indian generic manufacturers to produce lower-cost versions of the drug, potentially improving access for patients with heart failure and hypertension. 这一举动强调了印度严格的专利标准,特别是在第3(d)节下,这需要真正的治疗优势。 The move underscores India's strict patent standards, particularly under Section 3(d), which requires genuine therapeutic advantages. Vymada是2024年全球最大销售额78亿美元的药物,可能面临诺华的法律挑战,但这项裁决支持近三分之一成年人血压高的国家提供负担得起的药品。 Vymada, a top-selling drug generating $7.8 billion globally in 2024, may face legal challenges from Novartis, but the ruling supports affordable medicine access in a country where nearly a third of adults have high blood pressure.